CapsoVision earnings release, May 14, 2026

CapsoVision, Inc (CV) · Form 8-K, Item 2.02 · Filed · SEC filing

CapsoVision Reports First Quarter 2026 Financial Results

SARATOGA, Calif., May 14, 2026 - CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for its first quarter ended March 31, 2026.

Recent Highlights

• Delivered first quarter revenue of $2.8 million, stable compared to the first quarter of 2025.

• Existing customers continued to expand clinical use of CapsoCam Plus® for small bowel disease detection, while procedure volume demonstrated growing adoption and end-user consumption.

• Secured key customer renewals with large GI networks, including Indiana University Health Systems, Providence Health Systems, and Gastro Health, reinforcing platform value and long-term relationships.

• CapsoCam Plus® used by over 167,000 patients as of March 31, 2026.

• CapsoVision’s AI-assisted reading feature for CapsoCam Plus, on track for anticipated FDA clearance mid-year, with commercial launch expected shortly thereafter, subject to FDA review timelines.

• Pipeline programs progressing as planned, including our second-generation of CapsoCam Colon with 510(k) submission expected in the third quarter of 2026, and initiation of a clinical study for CapsoCam UGI in pancreatic cancer detection with the first patient enrolled in May 2026.

• Completed a $14 million private placement of public equity financing on March 16, 2026.

Management Commentary

“We saw continued strength in underlying utilization during the first quarter, reflecting deeper engagement across our installed base and the increasing role CapsoCam Plus® is playing in clinical practice,” said Johnny Wang, President and Chief Executive Officer of CapsoVision. “Importantly, we also secured key renewals with large GI networks, reinforcing the durability of our customer relationships and the value of our platform.

"At the same time, we are approaching an important inflection point with the anticipated FDA clearance of our AI-assisted reading feature for CapsoCam Plus®, which we believe will further enhance workflow efficiency for physicians and we received positive feedback at recent industry meetings. Across the pipeline, we remain on track, including progress on the second-generation of our CapsoCam Colon capsule and the recent initiation of our pancreatic cancer study with initial patient enrollment. Taken together, we believe we are well positioned to continue advancing our platform and executing on our long-term strategy.”

First Quarter 2026 Financial Results

Total revenue was $2.8 million, stable compared to $2.8 million in the first quarter of 2025, due to a 3% decrease in capsule volume, offset by a slight increase in average selling price.

Gross profit was $1.3 million, a decrease of $0.2 million, or 11%, compared to $1.5 million in the first quarter of 2025. Gross margin was 48%, compared to 54% in the first quarter of 2025. The decrease was due to the impact of changes in U.S. trade policies and tariffs.

Operating expenses were $8.4 million, a $1.5 million increase from the first quarter of 2025, driven primarily by the development of the new CMOS image sensors under the development agreement with Canon Inc., as well as clinical trial activities supporting the second-generation of CapsoCam Colon.

Cash and cash equivalents totaled $17.9 million as of March 31, 2026.

On March 16, 2026, the Company closed a $14 million private placement in public equity financing.

Conference Call and Webcast

CapsoVision will host a conference call today, May 14, 2026, at 4:30 p.m. ET to discuss its first quarter financial results. Individuals interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and referencing conference ID 5439091, or from the webcast link on the Events page in the investor relations section of the company's website at www.capsovision.com.

To access the replay, please register via the webcast link on the Events page. The webcast will be available for one year following the completion of the call.

About CapsoVision

CapsoVision is a commercial-stage medical technology company focused on developing advanced imaging and AI-enabled solutions to transform the detection and screening of gastrointestinal diseases. Its flagship product, CapsoCam Plus®, is a wire-free, panoramic capsule endoscope that enables high-resolution visualization of the small bowel and supports cloud-based or direct capsule video retrieval. The Company’s next pipeline product, CapsoCam Colon™ with enhanced AI, is designed to enable non-invasive colon imaging and polyp detection. With a proprietary platform targeted to expand across multiple GI indications, including esophageal and pancreatic disorders, CapsoVision is advancing a new era in capsule-based diagnostics. For more information on CapsoVision, please visit www.capsovision.com.

Financial statements

Income Statement

Three Months Ended March 31, — (in thousands, except share and per-share amounts)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Net revenue2,7922,783
Costs of revenue1,4631,289
Gross profit1,3291,494
OPERATING EXPENSESSelling and marketing2,0911,961
OPERATING EXPENSESResearch and development4,4353,107
OPERATING EXPENSESGeneral and administrative1,8961,808
OPERATING EXPENSESTotal operating expenses8,4226,876
OPERATING EXPENSESOperating loss-7,093-5,382
NON-OPERATING INCOMEInterest income, net596
NON-OPERATING INCOMEOther non-operating income, net11
NON-OPERATING INCOMETotal non-operating income, net607
NON-OPERATING INCOMELoss before income taxes-7,033-5,375
NON-OPERATING INCOMENet loss and comprehensive loss-7,033-5,375
NON-OPERATING INCOMENet loss per share – basic and diluted-0.15-2.49
NON-OPERATING INCOMEWeighted average common shares outstanding – basic and diluted47,456,9082,157,627

Balance Sheet

March 31, 2026 — (in thousands, except par value and share amounts)

March 31, 2026December 31, 2025
Current AssetsCash and cash equivalents17,93310,112
Current AssetsAccounts receivable, net1,9252,498
Current AssetsInventory3,4912,987
Current AssetsPrepaid expenses and other current assets1,1511,072
Current AssetsTotal current assets24,50016,669
Current AssetsProperty and equipment, net620611
Current AssetsOperating lease right-of-use assets749843
Current AssetsOther long-term assets7641
Current AssetsTOTAL ASSETS25,94518,164
Current LiabilitiesAccounts payable1,3591,143
Current LiabilitiesAccrued expenses and other current liabilities3,4942,697
Current LiabilitiesDeferred revenue84177
Current LiabilitiesOperating lease liabilities – current426410
Current LiabilitiesTotal current liabilities5,3634,427
Current LiabilitiesOperating lease liabilities – long-term362477
Current LiabilitiesTotal liabilities5,7254,904

Balance Sheet

(in thousands, except par value and share amounts)

Stockholders’ EquityCommon stock, $0.001 par value: 300,000,000 and 300,000,000 shares authorized; 49,838,867 and 46,865,051 issued and outstanding as of March 31, 2026 and December 31, 2025, respectively5047
Stockholders’ EquityAdditional paid-in capital182,868168,878
Stockholders’ EquityAccumulated deficit-162,698-155,665
Stockholders’ EquityTotal stockholders’ equity20,22013,260
Stockholders’ EquityTOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY25,94518,164

Cash Flow

Three Months Ended March 31, — (in thousands)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
CASH FLOWS FROM OPERATING ACTIVITIESNet loss-7,033-5,375
Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization5652
Adjustments to reconcile net loss to net cash used in operating activities:Loss on disposal of property and equipment1
Adjustments to reconcile net loss to net cash used in operating activities:Amortization of operating lease right-of-use assets9485
Adjustments to reconcile net loss to net cash used in operating activities:Unrealized foreign exchange gains-4-12
Adjustments to reconcile net loss to net cash used in operating activities:Stock-based compensation334152
Adjustments to reconcile net loss to net cash used in operating activities:Bad debt expense11
Changes in operating assets and liabilities:Accounts receivable594296
Changes in operating assets and liabilities:Inventory-504-408
Changes in operating assets and liabilities:Prepaid expenses and other current assets8-621
Changes in operating assets and liabilities:Other long-term assets-35
Changes in operating assets and liabilities:Accounts payable198134
Changes in operating assets and liabilities:Accrued expenses and other current liabilities417833
Changes in operating assets and liabilities:Deferred revenue-93-48
Changes in operating assets and liabilities:Operating lease liabilities-99-85
Changes in operating assets and liabilities:Net cash used in operating activities-6,066-4,986
CASH FLOWS FROM INVESTING ACTIVITIESPurchases of property and equipment-48-40
CASH FLOWS FROM INVESTING ACTIVITIESNet cash used in investing activities-48-40
CASH FLOWS FROM FINANCING ACTIVITIESProceeds from Private Placement14,000
CASH FLOWS FROM FINANCING ACTIVITIESPayment of Private Placement issuance costs-87
CASH FLOWS FROM FINANCING ACTIVITIESProceeds from exercises of options on common stock and warrants3934
CASH FLOWS FROM FINANCING ACTIVITIESNet cash provided by financing activities13,95234
CASH FLOWS FROM FINANCING ACTIVITIESNet increase (decrease) in cash and cash equivalents7,838-4,992
CASH FLOWS FROM FINANCING ACTIVITIESEffect of exchange rate changes on cash and cash equivalents-1771
CASH FLOWS FROM FINANCING ACTIVITIESCash and cash equivalents at beginning of period10,1129,319
CASH FLOWS FROM FINANCING ACTIVITIESCash and cash equivalents at end of period17,9334,398
NON-CASH FINANCING AND INVESTING ACTIVITIESPrivate Placement issuance costs in accounts payable and accruals380
Full release

Forward-Looking Statements... (truncated)soCam Plus® and commercial launch expected shortly thereafter), the Company’s plans, strategies and timing for its pipeline development (including the study for second-generation of CapsoCam Colon and related 510(k) submission, and the clinical study for CapsoCam UGI in pancreatic cancer detection) and the success of the Company’s plans and strategies. These forward-looking statements are based on the Company’s current expectations and inherently involve significant risks and uncertainties, including those beyond the Company’s control. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, market conditions, the Company’s financial condition and the availability of cash and financing, the success of the Company’s product and clinical development efforts, the failure to receive regulatory clearance and the failure to adapt the Company’s products for new indications. These and other risks and uncertainties are described more fully in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s most recent Form 10-K and Form 10-Q. Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise these statements, except as required by law.

Investor Relations Contact

Leigh Salvo

New Street Investor Relations

Investors@CapsoVision.com

Media Contact

Leslie Strickler and Paul Spicer

Être Communications leslies@etrecommunications.com

(804) 240-0807

pauls@etrecommunications.com

(804) 503-9231

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · CapsoVision earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.